Elliott Antman, MD is Professor of Medicine and Associate Dean for Clinical/Translational Research at Harvard Medical School, a Senior Investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, a Senior Physician in the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, Massachusetts. He was President of the American Heart Association (2014-2015). The American Heart Association honored him with the 2016 Paul Dudley White Award.
As a Senior Investigator in the TIMI Study Group, he has published on the use of serum cardiac markers for diagnosis and prognosis of patients with unstable angina and acute myocardial infarction, cyclooxygenase and cardiovascular risk, and antithrombotic therapy for acute coronary syndromes. His ongoing research studies help refine diagnostic and therapeutic modalities in routine clinical use today including cardiac specific troponins and novel antithrombotic agents.
At Brigham and Women’s Hospital, Dr. Antman has been recognized for his active role and interest in education and training. He is the recipient of many awards from the housestaff and has been honored for his contributions by the Harvard Medical School when it awarded him the A. Clifford Barger Excellence in Mentoring Award. Dr. Antman is Director of the Skills Development Center of the Boston Biomedical Innovation Center at the Brigham and Women’s Hospital.
Dr. Antman is the Director of the Harvard Catalyst Program for Education in Clinical and Translational Science. The goal of this program is to establish the infrastructure for coordination, integration, and oversight of clinical/translational postgraduate educational and training opportunities throughout the entire Harvard University system.
Dr. Antman participates actively in American Heart Association (AHA) and American College of Cardiology (ACC) activities, locally, nationally, and internationally. He was the Chairman of the joint ACC/AHA Task Force on Practice Guidelines from January 2003 through December 2005. From 2011-12, Dr. Antman chaired the AHA’s Committee on Scientific Sessions Programs and introduced the AHA’s Emerging Science Webinar Series. Dr. Antman was on the AHA’s National Board of Directors, chaired the AHA Science and Advisory Coordinating Committee, chaired the AHA Advocacy Coordinating Committee, and chaired the AHA Manuscript Oversight Committee. He is chair of the AHA International Science and Programs Subcommittee of the International Committee. He is the recipient of the Meritorious Achievement Award from the AHA and is the recipient of the James B. Herrick Award for Outstanding Achievement in Clinical Cardiology (Council on Clinical Cardiology).
Dr. Antman is married to Dr. Karen Antman, who is the Dean of Boston University School of Medicine and Provost of the Boston University Medical Center.
Robert P. Giugliano, MD, SM is a Senior Investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Staff Physician in the Cardiovascular Division at the Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. He graduated summa cum laude and phi beta kappa, and received his medical degree at Harvard Medical School. Dr. Giugliano completed his internship, residency, and chief residency at Cedars-Sinai Medical Center, Los Angeles and then returned to Boston as a Cardiology Fellow at the Massachusetts General Hospital.
Dr. Giugliano joined the Brigham and Women’s Hospital in 1996, worked with the TIMI Study Group, and completed a Master of Science degree in epidemiology at the Harvard School of Public Health and joined the Cardiovascular Division in 1997.
His research interests include novel antithrombotic therapies for atrial fibrillation and acute coronary syndromes (ACS), lipid-lowering therapies and the assessment of outcomes in patients with ACS. Dr. Giugliano has authored more than 250 original articles and 150 reviews/editorials/book chapters. He is the Founding Scientific Advisor and Editor-in-Chief for MD Conference Express, Co-Editor-in-Chief of Cardiology and Therapy, and serves on editorial boards for Circulation, The American Heart Journal, Clinical Cardiology, Cor et Vasa, Hospital Practice, Cardiovascular Therapeutics and Clinical Pathways in Cardiology.
Dr. Giugliano is the Principal TIMI Investigator for the ENGAGE AF-TIMI 48, LAPLACE-TIMI 57 and EARLY ACS trials, ANTHEM-TIMI 32 and Executive Committee member of the IMPROVE-IT. FOURIER, and EBBINGHAUS trials.
David A. Morrow, MD, MPH is the Director of the Samuel A. Levine Cardiac Intensive Care Unit in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital and a Professor of Medicine at Harvard Medical School. Dr. Morrow earned his medical degree from Harvard Medical School and a Masters in Public Health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He completed his medical residency in Internal Medicine and fellowship in Cardiovascular Medicine at Brigham and Women’s Hospital.
Dr. Morrow is a Senior Investigator in the Thrombolysis in Myocardial Infarction Study Group at Brigham and Women’s Hospital with a research focus in the management of unstable and stable coronary artery disease. He also directs the TIMI Biomarker Program.
Dr. Morrow is an internationally recognized expert in risk stratification in patients with ischemic heart disease. He has served on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers for which he led the clinical section on acute coronary syndromes, and on the Program Committee for the American Heart Association Council on Clinical Cardiology. He is a member of the Global Task Force for a Universal Definition of Myocardial Infarction and of the American College of Cardiology/American Heart Association Guidelines Committee for Management of ST-elevation Myocardial Infarction. He sits on the editorial boards of the American Heart Journal, Circulation, Clinical Chemistry, European Heart Journal: Acute Cardiovascular Care, and the Journal of the American College of Cardiology. He has been a special section Co-Editor for Continuing Medical Education at Circulation. Dr. Morrow has more than 150 original scientific reports, reviews, editorials, book chapters and electronic publications in his areas of expertise, and is the editor of Cardiovascular Biomarkers, a text on application of biomarkers in Cardiovascular disease.
Stephen D. Wiviott, MD, FACC is a graduate of University of Pennsylvania and Harvard Medical School (HMS, Honors). He served as a Medicine resident and Chief Medical Resident at Brigham and Women’s Hospital (BWH). Following his medical residency training, he served as a Cardiology fellow at Johns Hopkins Hospital. He is Associate Professor of Medicine at Harvard Medical School, and a Senior Investigator with the TIMI Study Group. He attends in the Lown Cardiovascular Intensive Care Unit and general Cardiology service at BWH.
As an investigator, Dr. Wiviott has played important roles in the planning, implementation, leadership, and interpretation of multicenter, national, and international clinical trials in acute coronary syndromes including the TRITON-TIMI 38 trial, PRINCIPLE-TIMI 44 and of the TIMI 38 Coronary Stent Registry. He has also served in leadership of trials of secondary prevention of cardiovascular disease as global PI of DECLARE – TIMI 58 and CAMELLIA – TIMI 61, assessing CV safety and efficacy of metabolic therapies. He is the Chairman of the TIMI Clinical Events Committee and recognized as an expert in event definitions and adjudications. Dr. Wiviott is an author of nearly 200 peer-reviewed publications in major medical and cardiovascular journals. He was named in 2014 and 2017 by Thomson Reuters and Clarivate Analytics as one of “The World’s Most Influential Scientific Minds”, and in 2016 as a “Highly Cited Researcher,” recognitions inclusive of the top 1% of researchers in Clinical Medicine by citation.
Building on his trials experience, Dr. Wiviott was appointed Executive Director of the Clinical Trials Office (CTO) for Partners HealthCare. The CTO provides contracting, budgeting, and clinical trial management services for Partners hospital investigators and industry sponsors and is tasked with supporting and growing clinical trials research at Partners.
Benjamin Scirica, MD, MPH graduated from Harvard Medical School and trained in internal medicine and cardiovascular medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He has a Master of Public Health degree from Harvard School of Public Health. He is currently Associate Professor of Medicine at Harvard Medical School and Senior Investigator at the TIMI Study Group. He is Director of Innovation in the cardiovascular division at Brigham and Women’s Hospital.
His research interests center on the identification and application of novel cardiac biomarkers and therapeutic strategies across the spectrum of cardiometabolic disease. He was principal investigator of the AVANT GARDE-TIMI 43 trial and CAMELLIA-TIMI 61 and co-investigator of the MERLIN-TIMI 36, TRA 2Pº-TIMI 50, and SAVOR-TIMI 53 trials. He is the Director of the TIMI ECG Core Laboratory, which has analyzed over 20,000 continuous and static ECGs from multiple trials in acute coronary syndromes.
Dr. Scirica has authored or co-authored over 100 peer-reviewed articles, serves on the editorial board of ACCEL, and is a reviewer for multiple journals, including The Lancet, Circulation and Journal of the American College of Cardiology (JACC). He practices in the Levine Cardiac Intensive Care Unit, cardiology in-patient service, and the Watkins Cardiovascular Clinic at Brigham and Women’s Hospital.
Michelle O’Donoghue, MD, MPH is an Associate Physician in the Cardiovascular Division of Brigham and Women’s Hospital, an Affiliate Physician in the Cardiovascular Division of Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. She has been working as an investigator with the TIMI Study Group since 2005.
Dr. O’Donoghue’s primary research focus is the design and conduct of multicenter clinical trials for patients with stable and unstable heart disease, in addition to other related disease states. She acted as the co-Principal Investigator of the global SOLID-TIMI 52 trial, the phase III randomized trial of the direct Lp-PLA2 inhibitor darapladib in patients after an acute coronary syndrome. She also served as the National Lead Investigator for the LATITUDE-TIMI 60 trial, the phase III randomized trial of losmapimod in ACS patients. She is currently serving as a National Coordinator for the HPS-4/TIMI 55 ORION-4 trial, the phase III trial of the novel PCSK9 inhibitor inclisiran. Prior trial leadership includes the PRINCIPLE-TIMI 44 trial (a pharmacodynamic study of prasugrel versus clopidogrel in PCI) and the LANCELOT phase II program of the PAR-1 antagonist atopaxar. She has been the project Principal Investigator for the cardiovascular risk assessment of two investigational therapeutics in the field of bone metabolism. She was the local Principal Investigator of the PEGASUS-TIMI 54 trial (ticagrelor in patients with a history of myocardial infarction) and the CAMELLIA-TIMI 61 trial (lorcaserin in overweight patients with cardiovascular disease or risk factors). Additional clinical research interests include the evaluation of novel antiplatelet drugs, established and novel biomarkers, the study of women and heart disease and the development of novel therapeutics in the management of acute coronary syndromes and diabetes mellitus.
Dr. O’Donoghue earned her medical degree from Columbia University College of Physicians and Surgeons in New York. She completed her residency in internal medicine and fellowship in cardiovascular medicine at Massachusetts General Hospital. She subsequently completed a Masters in Public Health degree at the Harvard School of Public Health.